# Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution

> **NCT02325518** · PHASE4 · COMPLETED · sponsor: **Alcon, a Novartis Company** · enrollment: 218 (actual)

## Conditions studied

- Open-Angle Glaucoma
- Ocular Hypertension

## Interventions

- **DRUG:** Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension
- **DRUG:** Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution
- **DRUG:** Subject's habitual PGA monotherapy

## Key facts

- **NCT ID:** NCT02325518
- **Lead sponsor:** Alcon, a Novartis Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2016-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02325518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02325518, "Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02325518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*